comparemela.com

Latest Breaking News On - Prognosis consortium - Page 1 : comparemela.com

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight semaglutide's benefits for kidney function and overall cardiovascular health.

Risk Calculator for Early-Stage CKD May Soon Enter US Market

Race-Free eGFR, Albuminuria Predict 10 Adverse Outcomes - Renal and Urology News

Large international study confirms the importance of albuminuria in risk assessment. Investigators studied eGFR and albuminuria data from more than 27 million adults and their risk for 10 key adverse outcomes.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.